ReviewGut and liver2020
Detecting Early Pancreatic Cancer: Current Problems and Future Prospects.
Review in Gut and liver, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Perioperative pancreatic ductal adenocarcinoma care in 2025: who needs neoadjuvant?-who needs radiation?Gland surgery · 2026Review
- Peptides as integrative modulators for clinical prognosis and targeted therapy in pancreatic cancer.Discover oncology · 2026Review
- The effect on gastrointestinal peristalsis for magnetic resonance cholangiopancreatography during breath-holding methods.Radiological physics and technology · 2024Article
- The high FKBP1A expression in WBCs as a potential screening biomarker for pancreatic cancer.Scientific reports · 2024Article
- Contrast-Enhanced Computed Tomography and Laboratory Parameters as Non-Invasive Diagnostic Markers of Pancreatic Fibrosis.Diagnostics (Basel, Switzerland) · 2023Article
- Article
- Suspicious findings observed retrospectively on CT imaging performed before the diagnosis of pancreatic cancer.Journal of gastrointestinal oncology · 2023Article
- Oral mycobiota and pancreatic ductal adenocarcinoma.BMC cancer · 2022Article
- Diagnostic Strategy of Early Stage Pancreatic Cancer via Clinical Predictor Assessment: Clinical Indicators, Risk Factors and Imaging Findings.Diagnostics (Basel, Switzerland) · 2022Article
- Oral microbiome and pancreatic cancer.World journal of gastroenterology · 2020Article
- Screening Strategy of Pancreatic Cancer in Patients with Diabetes Mellitus.Diagnostics (Basel, Switzerland) · 2020Review
- Pancreatic Fibrosis and Chronic Pancreatitis: Mini-Review of Non-Histologic Diagnosis for Clinical Applications.Diagnostics (Basel, Switzerland) · 2020Review
- Nanomedicine for Imaging and Therapy of Pancreatic Adenocarcinoma.Frontiers in bioengineering and biotechnology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of patients with pancreatic cancer (PC) is currently increasing in both Korea and Japan. The 5-year survival rate of patients with PC 13.0%; however, resection with minimal invasion (tumor size: ≤10 mm) increases the 5-year survival rate to 80%. For this reason, early detection is essential, but most patients with early-stage PC are asymptomatic. Early detection of PC has been reported to require screening of high-risk individuals (HRIs), such as those with a family history of PC, inherited cancer syndromes, intraductal papillary mucinous neoplasm, or chronic pancreatitis. Studies on screening of these HRIs have confirmed a significantly better prognosis among patients with PC who were screened than for patients with PC who were not screened. However, to date in Japan, most patients with early-stage PC diagnosed in routine clinics were not diagnosed during annual health checks or by surveillance; rather, PC was detected in these patients by incidental findings during examinations for other diseases. We need to increase the precision of the PC screening and diagnostic processes by introducing new technologies, and we need to pay greater attention to incidental clinical findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.